Product Categories
| Country: | China |
|---|---|
| Tel: | 177-54423994 |
| Mobile: | 17754423994 |
| E-mail: | |
| QQ: | |
| Skype: | Chat Now! |
| Product Name | MF | CAS | Details |
|---|
| 1-Piperidinamine, N-hydroxy-N-nitroso- | C5H11N3O2 | 56329-24-9 | Details |
| Navivumab | 1443004-16-7 | Details |
| Trevogrumab | 1429201-24-0 | Details |
| Afasevikumab | 1589503-30-9 | Details |
| Lanadelumab | 1426055-14-2 | Details |
| Dezamizumab | 1662664-56-3 | Details |
| Aprutumab | 1634620-63-5 | Details |
| Garetosmab | 2097125-54-5 | Details |
| Amivantamab | 2171511-58-1 | Details |
| JQKD-82 | C27H40N4O5 | 2410512-38-6 | Details |
| ML339 | C26H32ClN3O5 | 2579689-83-9 | Details |
| INE963 | C19H26N6O2S | 2640567-43-5 | Details |
| OTX 008 | C52H72N8O8 | 286936-40-1 | Details |
| Enoblituzumab | 1353485-38-7 | Details |
| SBI-425 | C13H12ClN3O4S | 1451272-71-1 | Details |
| Mc-Val-Ala-PAB-PNP | C32H37N5O10 | 1639939-40-4 | Details |
| Bermekimab | 1401965-15-8 | Details |
| Inebilizumab | 1299440-37-1 | Details |
| Ranevetmab | 1632282-27-9 | Details |
| Sigma-1 receptor antagonist 2 | C20H26ClN3O2 | 1639220-15-7 | Details |
| Birtamimab | 1608108-91-3 | Details |
| Rozanolixizumab | 1584645-37-3 | Details |
| Camrelizumab | 1798286-48-2 | Details |
| JYN42346 | C27H24BrN7O3 | 1903742-34-6 | Details |
| TH5427 | C20H20Cl2N8O3 | 2253744-56-6 | Details |
| Zunsemetinib | C25H22ClF2N5O3 | 1640282-42-3 | Details |
| 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione | C10H11F3N2O5 | 1380532-27-3 | Details |
| Lacutamab | 2187368-16-5 | Details |
| Indusatumab Vedotin | 1514889-12-3 | Details |
| Galcanezumab | 1578199-75-3 | Details |
| Istiratumab | 1509928-04-4 | Details |
| Rinucumab | 1569263-06-4 | Details |
| Tilavonemab | 2096513-89-0 | Details |
| Carotuximab | 1268714-50-6 | Details |
| Elezanumab | 1791416-49-3 | Details |
| Brazikumab | 1610353-18-8 | Details |
| Tomaralimab | 1449294-76-1 | Details |
| Monalizumab | 1228763-95-8 | Details |
| Refanezumab | 1233953-61-1 | Details |
| Suptavumab | 1629615-23-1 | Details |
| Lupartumab | 1640971-88-5 | Details |
| Emapalumab | 1709815-23-5 | Details |
| Boc-Val-Ala-PAB-PNP | C27H34N4O9 | 1884578-00-0 | Details |
| Andecaliximab | 1518996-49-0 | Details |
| Plozalizumab | 1610761-46-0 | Details |
| Satralizumab | 1535963-91-7 | Details |
| Blontuvetmab | 1608112-78-2 | Details |
| Utomilumab | 1417318-27-4 | Details |
| SR1664 | C33H29N3O5 | 1338259-05-4 | Details |
| Pepinemab | 2097151-87-4 | Details |
| Timolumab | 1073538-99-4 | Details |
| Lutikizumab | 1791411-57-8 | Details |
| Telisotuzumab | 1781223-80-0 | Details |
| Maftivimab | 2135632-36-7 | Details |
| Varisacumab | 1610010-60-0 | Details |
| Ensitrelvir fumarate | C26H21ClF3N9O6 | 2757470-18-9 | Details |
| RY785 | C21H20N4O2S | 1393748-80-5 | Details |
| Eptinezumab | 1644539-04-7 | Details |
| Fremanezumab | 1655501-53-3 | Details |
| Obiltoxaximab | 1351337-07-9 | Details |
| Erucin | C6H11NS2 | 4430-36-8 | Details |
| Indusatumab | 1497400-26-6 | Details |
| Bleselumab | 1453067-91-8 | Details |
| Ifabotuzumab | 1234137-51-9 | Details |
| Mirvetuximab | 1453084-36-0 | Details |
| Setrusumab | 1847394-95-9 | Details |
| Depatuxizumab | 1471999-69-5 | Details |
| Crizanlizumab | 1690318-25-2 | Details |
| 2,4-Imidazolidinedione, 5-[3-[[4-[(3-methylphenyl)methoxy]phenyl]thio]-2-furanyl]- | C21H18N2O4S | 877176-23-3 | Details |
| YM150 | C27H30N4O4 | 365462-23-3 | Details |
| Clivatuzumab Tetraxetan | 1462876-11-4 | Details |
| Cabiralizumab | 1613144-80-1 | Details |
| Tamtuvetmab | 1608122-71-9 | Details |
| Erenumab | 1582205-90-0 | Details |
| Duvortuxizumab | 1831098-91-9 | Details |
| Vunakizumab | 1792181-33-9 | Details |
| Losatuxizumab | 1801544-27-3 | Details |
| GSK251 | C29H37FN6O4S | 2125968-05-8 | Details |
| YTX-465 | C25H26N6O3 | 2225824-53-1 | Details |
| (R)-GSK-3685032 | C22H24N6OS | 2170140-50-6 | Details |
| Risankizumab | 1612838-76-2 | Details |
| Ravulizumab | 1803171-55-2 | Details |
| BioE-1197 | C20H18FN3O2 | 1268863-69-9 | Details |
| MRTX1719 | C23H18ClFN6O2 | 2630904-45-7 | Details |
| Bocidelpar | C25H27F3N2O3 | 2095128-20-2 | Details |
| SCD1 inhibitor-3 | C19H16FN7O2 | 1282606-48-7 | Details |
| FTO-IN-3 | C12H10N4OS | 2585198-87-2 | Details |
| GI 181771 | C34H31N5O6 | 305366-98-7 | Details |
| Xentuzumab | 1417158-65-6 | Details |
| Rovalpituzumab | 1613313-01-1 | Details |
| Ascrinvacumab | 1463459-96-2 | Details |
| Lilotomab | 1453362-55-4 | Details |
| Ro60-0175 | C11H12ClFN2 | 169675-08-5 | Details |
| AZD-1940 | C20H29F2N3O2S | 881413-29-2 | Details |
| SUC-ALA-ALA-PRO-PHE-PNA | C30H34N6O8 | 107409-54-1 | Details |
| Flotetuzumab | 1664355-28-5 | Details |
| Vonlerolizumab | 1638935-72-4 | Details |
| Olendalizumab | 1337966-73-0 | Details |
| Tisotumab | 1418628-81-5 | Details |
| Opicinumab | 1422268-07-2 | Details |
| Product Total： Product Page： | ||||
| 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 | ||||